NAMS
NewAmsterdam Pharma Company N.V.
$36.03
+$0.59(+1.66%)
57
Overall
50
Value
66
Tech
55
Quality
Market Cap
$3.94B
Volume
505.88K
52W Range
$16.79 - $42.21
Target Price
$50.92
Company Overview
| Mkt Cap | $3.94B | Price | $36.03 |
| Volume | 505.88K | Change | +1.66% |
| P/E Ratio | -19.3 | Open | $35.88 |
| Revenue | $22.5M | Prev Close | $35.44 |
| Net Income | $-203.8M | 52W Range | $16.79 - $42.21 |
| Div Yield | N/A | Target | $50.92 |
| Overall | 57 | Value | 50 |
| Quality | 55 | Technical | 66 |
No chart data available
About NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Latest News
Wall Street Analysts Are Bullish on Top Healthcare Picks
Catie Powers•18 days ago
Wall Street Analysts Are Bullish on Top Healthcare Picks
Howard Kim•19 days ago
H.C. Wainwright Sticks to Their Buy Rating for NewAmsterdam Pharma Company (NAMS)
TipRanks Auto-Generated Intelligence Newsdesk•19 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | NAMS | $36.03 | +1.7% | 505.88K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get NewAmsterdam Pharma Company N.V. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW